WTO Rx Compulsory Licensing Agreement Solves “Symbolic” Issue, USTR Says
Executive Summary
World Trade Organization final agreement on drug compulsory licensing represents progress on a "symbolic" issue, Assistant U.S. Trade Representative for Services, Investment and Intellectual Property James Mendenhall said Sept. 2 at an American Enterprise Institute forum on the Trade-Related Aspects of Intellectual Property Rights agreement
You may also be interested in...
Rx Pricing Debate Must Be Framed As Trade Issue, Pfizer CEO Says
The pharmaceutical industry needs to re-cast the global pricing and reimportation debate as a trade issue, Pfizer CEO Henry McKinnell told the Bear Stearns conference in New York City Sept. 8
Rx Pricing Debate Must Be Framed As Trade Issue, Pfizer CEO Says
The pharmaceutical industry needs to re-cast the global pricing and reimportation debate as a trade issue, Pfizer CEO Henry McKinnell told the Bear Stearns conference in New York City Sept. 8
PhRMA Prepares For More TRIPS Import Talks; U.S. Lays Out “Interim Plan”
The Pharmaceutical Research & Manufacturers of America expects TRIPS negotiations on the importation of drugs made under compulsory license to resume within several weeks